神経バイオマーカーの市場規模、シェア、動向分析レポート：用途別、タイプ別、最終用途別、地域別、セグメント別予測、2024年～2030年

神経バイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の神経バイオマーカーの市場規模は、2024年から2030年にかけてCAGR 12.89％で拡大し、2030年までには187億5,000万米ドルに達する見込みです。

新薬開発を後押しする神経バイオマーカーの研究開発に対する資金提供の増加が、市場成長を後押しすると予想されます。National Institute of Neurological Disorders and Strokeは、臨床的検証、分析的検証、バイオマーカー発見に関連する研究を行う研究者に、共同研究契約や開発助成金などの資金提供の機会を提供しています。

バイオマーカーは神経疾患治療薬の開発に重要な役割を果たしています。近年、神経疾患の治療法の研究開発への投資が大幅に増加しています。例えば、2020年12月には、非営利研究財団であるTarget ALSが、ALSの新規バイオマーカーの発見に焦点を当てたプロジェクトに1,500万米ドルの研究資金を提供することを発表しており、予測期間中の市場成長が加速すると予想されます。

高いS/N比を持つデジタル化ELISA検査であるQuanterix Simoa（単一分子アレイ）のような技術的に先進的な製品の登場しました。この技術は、神経疾患関連のバイオマーカーに関連する血液脳関門の問題を克服するのに役立ちます。このような技術的進歩は市場の成長を促進すると予想されます。例えば、 Abbottは2021年1月、脳震盪を含む外傷性脳損傷のための初の迅速血液検査を発表しました。この検査は、外傷性脳損傷後に血液中に検出される特定のタンパク質を測定するもので、検査結果が陰性の場合、CTスキャンの必要性を除外するために使用できます。

特に発展途上国や低開発諸国では、このような診断製品に関する認識不足やその高コスト、神経科医の利用可能性の制限や不在といった要因が、このようなバイオマーカーに基づく診断ソリューションの採用に影響を与える可能性があります。世界神経学連合（World Federation of Neurology）がWHO加盟国63/84カ国を対象に行った調査によると、31/63カ国の神経科医の大多数は大都市に勤務していました。1人の神経科医が約6,240人から4,750,000人の人口にサービスを提供していました。

神経バイオマーカー市場レポートハイライト

• 2023年には、プロテオミクス型が最大の市場シェアを占め、予測期間中も優位性を維持すると予測されます。プロテオミクス型は、翻訳後修飾やタンパク質のシグネチャーを注意深く検出するため、疾患の発症や進行の正確な診断に不可欠だからです。
• パーキンソン病分野は、罹患率の上昇と研究開発活動の活発化により、最大の市場シェアを占めています。
• 最終用途別では、研究機関およびその他セグメントが神経バイオマーカー市場を独占しました。神経疾患の治療薬開発のために共同研究を行っている研究機関は、薬剤耐性を評価するためにバイオマーカーを利用しています。
• 北米は、米国とカナダに強力なプレゼンスを持つ市場プレイヤーの存在と、新規バイオマーカー開発のための政府資金の増加により、市場を独占しています。
• アジア太平洋地域は、日本やオーストラリアなどの先進国で技術的に先進的な診断製品の採用が進んでいること、中国やインドなどの新興経済諸国での採用が増加していることから、予測期間中に大きな成長が見込まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 神経バイオマーカーの市場変数、動向、および範囲

• 神経バイオマーカー市場系統の見通し
  • 親市場の見通し
• 普及と成長の見通しのマッピング
• パイプライン分析
  • アルツハイマー病
  • パーキンソン病
  • 多発性硬化症
  • 自閉症スペクトラム障害
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 神経バイオマーカー：市場分析ツール
  • 業界分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 神経バイオマーカー市場：セグメント分析、タイプ別、2018年～2030年

• 神経バイオマーカー市場：タイプの変動分析
  • ゲノム
  • プロテオミクス
  • メタボロミクス
  • イメージング
  • その他

第5章 神経バイオマーカー市場：セグメント分析、用途別、2018年～2030年

• 神経バイオマーカー市場：用途の変動分析
  • アルツハイマー病
  • パーキンソン病
  • 多発性硬化症
  • 自閉症スペクトラム障害
  • その他

第6章 神経バイオマーカー市場：セグメント分析、最終用途別、2018年～2030年

• 神経バイオマーカー市場：最終用途の変動分析
  • 病院および病院検査室
  • 独立した臨床診断センター
  • 調査機関等

第7章 神経バイオマーカー市場：セグメント分析、地域別、2018年～2030年

• 地域市場のスナップショット
• 北米
  • 北米の神経バイオマーカー市場、2018年～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州の神経バイオマーカー市場、2018年～2030年
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • アジア太平洋の神経バイオマーカー市場、2018年～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • タイ
  • オーストラリア
• ラテンアメリカ
  • ラテンアメリカの神経バイオマーカー市場、2018年～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの神経バイオマーカー市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 神経バイオマーカー市場：競争分析

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 買収
  • コラボレーション
  • 資金調達
• 企業の市場シェア分析、2022年
• 企業プロファイル
  • Abbott
  • Johnson &Johnson Services, Inc.
  • Bio-rad Laboratories, Inc.
  • Alseres Pharmaceuticals, Inc.
  • Banyan Biomarkers, Inc.
  • Rules-based Medicine
  • Thermo Fisher Scientific, Inc.
  • Diagenic Asa
  • Merck &Co., Inc.
  • Quanterix

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 11 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 12 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 13 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 14 U.K. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 15 U.K. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 16 U.K. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 17 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 18 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 19 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 20 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 21 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 22 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 23 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 24 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 25 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 26 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 27 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 28 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 29 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 30 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 31 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 32 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 33 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 34 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 35 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 36 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 37 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 38 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 39 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 41 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 42 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 43 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 44 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 45 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 46 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 47 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 48 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 49 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 50 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 51 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 52 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 53 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 54 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 55 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 56 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 57 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 58 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 59 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 60 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 61 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 62 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 63 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 64 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 65 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 66 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 67 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
• Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
• Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Neurological biomarkers market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot (Type and application)
• Fig. 11 Segment snapshot (End-use)
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Biomarkers market value, 2023 (USD Million)
• Fig. 14 Neurological biomarkers market dynamics
• Fig. 15 Prevalence of Alzheimer's disease by age group, 2023
• Fig. 16 Neurological biomarkers market: Porter's Five Forces analysis
• Fig. 17 Neurological biomarkers market: PESTLE analysis
• Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
• Fig. 19 Neurological biomarkers market: Type movement analysis
• Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
• Fig. 26 Neurological biomarkers market: Application movement analysis
• Fig. 27 Alzheimer's disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
• Fig. 33 Neurological biomarkers market: End-use movement analysis
• Fig. 34 Hospitals & hospital laboratories market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Independent clinical diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Research organizations and others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Neurological biomarkers market revenue, by region, 2023 & 2030 (USD Million)
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Key country dynamics
• Fig. 41 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Target disease prevalence
• Fig. 43 Key country dynamics
• Fig. 44 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Target disease prevalence
• Fig. 46 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Key country dynamics
• Fig. 48 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Key country dynamics
• Fig. 50 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Target disease prevalence
• Fig. 52 Key country dynamics
• Fig. 53 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 64 Target disease prevalence
• Fig. 65 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 66 Asia Pacific neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Target disease prevalence
• Fig. 70 Key country dynamics
• Fig. 71 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 Target disease prevalence
• Fig. 75 Key country dynamics
• Fig. 76 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 82 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Key country dynamics
• Fig. 84 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Key country dynamics
• Fig. 86 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Target disease prevalence
• Fig. 94 Key country dynamics
• Fig. 95 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Target disease prevalence
• Fig. 97 Key country dynamics
• Fig. 98 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Target disease prevalence
• Fig. 100 Key country dynamics
• Fig. 101 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 102 Target disease prevalence
• Fig. 103 Key payors in Kuwait
• Fig. 104 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 105 Key company categorization
• Fig. 106 Company market positioning
• Fig. 107 Company market share analysis, 2023
• Fig. 108 Strategic framework

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

• In 2023, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
• Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
• Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
• North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
• Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definition
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Type Segment
    • 1.1.1.3 End Use Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 GVR's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Type Snapshot
• 2.3 End Use Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

• 3.1 Neurological Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Pipeline Analysis
  • 3.3.1 Alzheimer's Disease
  • 3.3.2 Parkinson's Disease
  • 3.3.3 Multiple Sclerosis
  • 3.3.4 Autism Spectrum Disorder
• 3.4 Market Dynamics
  • 3.4.1 Market Driver Analysis
    • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
    • 3.4.1.2 Technological Advancements
    • 3.4.1.3 Increased Funding For R&d In Biomarkers
  • 3.4.2 Market Restraint Analysis
    • 3.4.2.1 Lack Of Consumer Awareness
    • 3.4.2.2 Reimbursement Policies
• 3.5 Neurological Biomarkers: Market Analysis Tools
  • 3.5.1 Industry Analysis - Porter's Five Forces
  • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

• 4.1 Neurological Biomarkers Market: Type Movement Analysis
  • 4.1.1 Genomic
    • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.2 Proteomic
    • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.3 Metabolomic
    • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.5 Imaging
    • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.6 Others
    • 4.1.6.1 Other Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 5.1 Neurological Biomarkers Market: Application Movement Analysis
  • 5.1.1 Alzheimer's Disease
    • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
  • 5.1.2 Parkinson's Disease
    • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
  • 5.1.3 Multiple Sclerosis
    • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
  • 5.1.4 Autism Spectrum Disorder
    • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
  • 5.1.5 Others
    • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End-use, 2018 - 2030 (USD Million)

• 6.1 Neurological Biomarkers Market: End-use Movement Analysis
  • 6.1.1 Hospital & Hospital Laboratories
    • 6.1.1.1 Hospitals & Hospital Laboratories Market, 2018 - 2030 (USD Million)
  • 6.1.2 Independent Clinical Diagnostic Centers
    • 6.1.2.1 Independent Clinical Diagnostic Centers Market, 2018 - 2030 (USD Million)
  • 6.1.3 Research Organizations And Others
    • 6.1.3.1 Research Organizations And Others Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Regional Market Snapshot
• 7.2 North America
  • 7.2.1 North America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Regulatory Framework
    • 7.2.2.4 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Regulatory Framework
    • 7.2.3.4 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.3.2 UK
    • 7.3.2.1 UK Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Regulatory Framework
    • 7.3.2.4 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Regulatory Framework
    • 7.3.3.4 Reimbursement Scenario
  • 7.3.4 Spain
    • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Regulatory Framework
    • 7.3.4.4 Reimbursement Scenario
  • 7.3.5 France
    • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Regulatory Framework
    • 7.3.5.4 Reimbursement Scenario
  • 7.3.6 Italy
    • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Regulatory Framework
    • 7.3.6.4 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Regulatory Framework
    • 7.3.7.4 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Regulatory Framework
    • 7.3.8.4 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Regulatory Framework
    • 7.3.9.4 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia-pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Regulatory Framework
    • 7.4.2.4 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Regulatory Framework
    • 7.4.3.4 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Regulatory Framework
    • 7.4.4.4 Reimbursement Scenario
  • 7.4.5 South Korea
    • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Regulatory Framework
    • 7.4.5.4 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Regulatory Framework
    • 7.4.6.4 Reimbursement Scenario
  • 7.4.7 Australia
    • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Regulatory Framework
    • 7.4.7.4 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
  • 7.5.3 Mexico
    • 7.5.3.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.4.2 Key Country Dynamics
    • 7.5.4.3 Regulatory Framework
    • 7.5.4.4 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Regulatory Framework
    • 7.6.3.4 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Regulatory Framework
    • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

• 8.1 Company Categorization
• 8.2 Strategy Mapping
  • 8.2.1 New Product Launches
  • 8.2.2 Partnerships
  • 8.2.3 Acquisitions
  • 8.2.4 Collaborations
  • 8.2.5 Funding
• 8.3 Company Market Share Analysis, 2022
• 8.4 Company Profiles
  • 8.4.1 Abbott
    • 8.4.1.1 Company Overview
    • 8.4.1.2 Financial Performance
    • 8.4.1.3 Product Benchmarking
    • 8.4.1.4 Strategic Initiatives
  • 8.4.2 Johnson & Johnson Services, Inc.
    • 8.4.2.1 Company Overview
    • 8.4.2.2 Financial Performance
    • 8.4.2.3 Product Benchmarking
    • 8.4.2.4 Strategic Initiatives
  • 8.4.3 Bio-rad Laboratories, Inc.
    • 8.4.3.1 Company Overview
    • 8.4.3.2 Financial Performance
    • 8.4.3.3 Product Benchmarking
    • 8.4.3.4 Strategic Initiatives
  • 8.4.4 Alseres Pharmaceuticals, Inc.
    • 8.4.4.1 Company Overview
    • 8.4.4.2 Product Benchmarking
  • 8.4.5 Banyan Biomarkers, Inc.
    • 8.4.5.1 Company Overview
    • 8.4.5.2 Product Benchmarking
    • 8.4.5.3 Strategic Initiatives
  • 8.4.6 Rules-based Medicine
    • 8.4.6.1 Company Overview
    • 8.4.6.2 Financial Performance
    • 8.4.6.3 Product Benchmarking
    • 8.4.6.4 Strategic Initiatives
  • 8.4.7 Thermo Fisher Scientific, Inc.
    • 8.4.7.1 Company Overview
    • 8.4.7.2 Financial Performance
    • 8.4.7.3 Product Benchmarking
    • 8.4.7.4 Strategic Initiatives
  • 8.4.8 Diagenic Asa
    • 8.4.8.1 Company Overview
    • 8.4.8.2 Product Benchmarking
  • 8.4.9 Merck & Co., Inc.
    • 8.4.9.1 Company Overview
    • 8.4.9.2 Financial Performance
    • 8.4.9.3 Product Benchmarking
    • 8.4.9.4 Strategic Initiatives
  • 8.4.10 Quanterix
    • 8.4.10.1 Company Overview
    • 8.4.10.2 Product Benchmarking
    • 8.4.10.3 Strategic Initiatives